For the biotech industry, 2020 was all about the race for a COVID-19 vaccine. By now, several have been authorized, a few additional candidates are beginning to cross the finish line ... and others have fallen by the wayside.
After reporting preliminary phase 1 results for its tablet vaccine candidate last week, Vaxart (NASDAQ: VXRT) was tossed into the category of misses, and its stock was crushed. Although the results were a disappointment, a possible silver lining -- and other vaccine programs -- could still deliver for shareholders.
Image source: Getty Images.
Source Fool.com